ROFDA announces Aggregated Data Cloud initiative
New capability designed to help ROFDA members and CPG partners better understand performance, opportunity, and void management across the independent grocery channel.
New capability designed to help ROFDA members and CPG partners better understand performance, opportunity, and void management across the independent grocery channel.
The findings suggest that snacks have become an essential part of how Americans experience everything from live sports and television premieres to casual nights spent catching up with friends.
Zebra highlighted as one of the best companies for the future in inaugural report.
Includes new advanced manufacturing and packaging technologies and a new state-of-the-art distribution facility to scale the company’s U.S. Vision operations.
A Circanan analysis suggests that strong sales and loyalty growth can hide market share declines, leading to the creation of Market Share Drivers, a tool to measure the effects of pricing, promotions, and other factors.
Lioness functional snack brand built for the real moments of her day.
The launch expands Camber’s hospital and acute care products and provides healthcare providers access to a widely used neuromuscular blocking agent for anesthesia and critical care.
For every free beard trim, men's grooming leader Wahl will donate $100 to veterans' charity.
Building on decade-long commitment to outbreak relief.
David Pinto examines the recent departure of Musab Balbale from CVS.
By Rich Kaminski is the research director at WSL Strategic Retail
The children's haircare brand built specifically for kids' hair and scalp brings its routine-first approach to more than 3,500 CVS locations nationwide.
The retail pipeline significantly increases the brand's footprint and accessibility, meeting young athletes and everyday consumers where they are in their shopping journey.
Moves span real estate, IT, business intelligence, human resources and store operations.
The supplement was created to resolve issues like constipation, nausea, and digestive discomfort caused by traditional iron products.
Phase 4 ELEVATE-PD interim data from the entire study population (n=214) continue to show clinically meaningful, consistent benefits of CREXONT across all prior treatment groups.